PDCD1 and melanoma: In all models, mPH-762 was well tolerated at the maximum administered dose of 2 mg/dose (0.05 mL of 40 mg/mL: q3d x5 (Hepa1-6, C57BL/6), q3d x4 (BP melanoma; C57BL/6; CT26, BALB/c) or q3d x3 B16-OVA, C57BL/6), such that treatments did not significantly impact cumulative weight gain compared to treatment with vehicle, NTC, or systemic (intraperitoneal; IP) anti-PD-1 mAb positive control (Supplementary Figure S5).